Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque
A matched cohort study (2842 pairs) and case-crossover analysis found risk of cardiovascular events was increased after starting an immune checkpoint inhibitor (HR 3.3; 95% CI 2.0-5.5; P<0.001), with an increase in CV events from 1.37 to 6.55 per 100 person-years at two years.
Source:
Circulation
SPS commentary:
The authors suggest the observed increased risk of cardiovascular events after initiation of immune checkpoint inhibitors could be mediated by accelerated progression of atherosclerosis, and they recommend that consideration be given to optimising cardiovascular risk factors and increasing awareness of cardiovascular risk.